IDEAYA Biosciences(IDYA) - 2024 Q3 - Quarterly Results

IDEAYA Biosciences, Inc. Reports Third Quarter 2024 Financial Results and Provides Business Update • Enrollment in darovasertib + crizotinib 1L HLA-A2+ MUM potential Ph2/3 registration-enabling trial is ahead of schedule and has exceeded 150 patients • Successful FDA Type C meeting and targeting initiation of Ph3 registration-enabling trial for darovasertib in neoadjuvant UM in H1 2025; Phase 2 neoadjuvant update with ~49% with >30% ocular tumor shrinkage & ~61% eyes preserved, and over 75 patients enrolled ...